• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

POSA107 Apixaban Versus Other Anticoagulants in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: A Comparison of All-Cause and Event-Related Costs in Real-Life Setting in France
To estimate and compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic embolism (SE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating apixaban and patients initiating other oral anticoagulants (OAC).
Source: Value in Health - January 1, 2022 Category: International Medicine & Public Health Authors: M Belhassen, O Hanon, PG Steg, I Mah é, M Née, F Jacoud, F Dalon, FE Cotte, S Gollety, C Marant-Micallef, E Van Ganse, B Falissard, N Danchin Source Type: research

One Year Cost Of Ischemic Stroke And Intracranial Hemorrage According To Disability For Atrial Fibrillation Patients In France
Patients with atrial fibrillation (AF) are at high risk of cerebral thromboembolic and hemorrhagic events, with potential residual disability. The aim of this research was to estimate the one-year costs of these events in the French context.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: G de Pouvourville, P Karam, M Giroud, C Le Dissez, L Luciani, K Le Lay Source Type: research